AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. AbbVie Inc. is one of them.

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader, continues to expand its presence in immunology, oncology, and neuroscience. The company has successfully transitioned from legacy drugs like Humira to newer blockbusters, including Skyrizi and Rinvoq, which treat inflammatory and autoimmune conditions and have shown strong sales growth of 71% and 57% year-over-year in 2025.

A major recent development is AbbVie Inc. (NYSE:ABBV)’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ mid-stage psychedelic drug candidate, bretisilocin, targeting major depressive disorder. This move marks the business’s strategic entry into neuroscience and psychiatry, diversifying its pipeline beyond immunology and oncology, positioning it among high growth stocks. In parallel, the firm is investing $195 million to expand API manufacturing at its North Chicago facility, part of a broader $10 billion U.S. investment plan over the next decade. The expansion, expected to begin operations in 2027, aims to strengthen domestic production capacity for next-generation therapies.

On the clinical front, AbbVie Inc. (NYSE:ABBV) reported positive topline results from a second Phase 3 trial evaluating Upadacitinib (Rinvoq) for alopecia areata, signaling potential growth in dermatological autoimmune indications. Combined with robust immunology sales and strategic investments, these developments highlight the company’s focus on innovation, pipeline diversification, and manufacturing resilience.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.